LYELL IMMUNOPHARMA INC (LYEL) — insider trading
Health Care · NASDAQ
LYELL IMMUNOPHARMA INC (LYEL) has 11 reported SEC Form 4 insider transactions in our data, including 6 open-market sales among the most recent 11 (latest 2026-07-17).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-17 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Open-market sale | 10 | $13.70 | $137 | Form 4 |
| 2026-07-16 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Open-market sale | 10 | $13.73 | $137 | Form 4 |
| 2026-06-29 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Other acquisition or disposition | 76,000 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Other acquisition or disposition | 66,500 | $0.00 | $0 | Form 4 |
| 2026-06-10 | NABEL ELIZABETH G | Director | Grant / award / vesting (derivative) | 9,250 | $0.00 | $0 | Form 4 |
| 2026-06-10 | Ramachandra Sumant | Director | Grant / award / vesting (derivative) | 9,250 | $0.00 | $0 | Form 4 |
| 2026-06-10 | RIEFLIN WILLIAM JL | Director | Grant / award / vesting (derivative) | 9,250 | $0.00 | $0 | Form 4 |
| 2026-05-11 | Bulis Veronica Sanchez | Officer (VP, Corporate Controller) | Open-market sale | 217 | $18.91 | $4.1K | Form 4 |
| 2026-05-11 | Hill Stephen J. | Officer (Chief Operating Officer) | Open-market sale | 89 | $18.92 | $1.7K | Form 4 |
| 2026-05-11 | Lee Gary K. | Officer (Chief Scientific Officer) | Open-market sale | 130 | $18.92 | $2.5K | Form 4 |
| 2026-05-11 | Seely Lynn | Director, Officer (President and CEO) | Open-market sale | 388 | $18.91 | $7.3K | Form 4 |
Ask the chat about LYEL's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: LYELL IMMUNOPHARMA INC (LYEL).
Last updated 2026-07-17 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.